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Several clinical, immunological and radiological 
biomarkers have been shown to predict the disease 
course of multiple sclerosis (MS).1–5 One potential 
serum marker is the gMS-Classifier1, which is com-
posed of IgM anti-Glc antibodies, namely anti-
GAGA 2,3,4 and 6. Previous work demonstrated that 
the gMS-Classifier1 could not predict early conver-
sion to clinically definite MS in a cohort of clinically 
isolated syndrome (CIS) patients, but predicted 
Expanded Disability Status Scale (EDSS) progres-
sion. Significance, however, was dependent on 
covariates, and confirmation in an independent study 
was required.3
The aim of this study was to test if the gMS-Classi-
fier1 could predict early disability progression in a 
large multicenter cohort of patients with CIS or 
relapse-onset MS.
Blood samples and clinical data were prospectively 
collected in four MS centers between 1993 and 2007: 
The Ottawa Hospital, Ottawa, Canada; Amsterdam 
University Medical Centers, the Netherlands; UMass 
Memorial Medical Center, Worcester, USA; and 
Hospital Ramón y Cajal, Madrid, Spain. Patients had 
a diagnosis of CIS (n = 118) or relapsing remitting 
multiple sclerosis (RRMS; n = 240) at study onset. 
Age at blood sampling was between 18 and 50 years. 
Serum samples were stored frozen <–70°C until 
assayed.
Baseline (EDSS) was performed within 6 months of 
blood sampling and was repeated during patient rou-
tine visits. Disability progression was defined as a 
sustained (⩾6 months) progression of at least 1.0 
EDSS point over the baseline EDSS and progression 
to an EDSS score of 3.0 or higher.
Mean follow-up was 94 months.
In 2012, frozen serum samples were shipped to 
Glycominds Inc Lab (Simi Valley, CA, USA) for test-
ing for anti-glycan antibodies as described before.3 If 
one of the antibodies was above the predefined cut-off 
(anti-GAGA2 >148.8 EIA units, anti-GAGA3 
>164.6 EIA units, anti-GAGA4 >133.6 EIA units, 
and anti-GAGA6 >168.1 EIA units), patients were 
considered positive for the gMS-Classifier1. There 
were no significant differences for the key variables 
gMS-Classifier1 and EDSS progression between the 
four centers.
Of the 358 patients, 44 (12.3%) were gMS-Classifier1 
status positive. EDSS progression was available for 
355 patients, of whom 158 (44.5%) had confirmed 
progression at the end of follow-up. The percentage of 
patients showing EDSS progression did not differ 
between the groups, using the 1 point EDSS progres-
sion definition (p = 0.587) or for EDSS progression 
above 3.0 (p = 0.771). There was no association 
between EDSS progression and the gMS-Classifier1 
(p = 0.778) or positive titres for any of the separate 
antibodies (anti-GAGA2: p = 0.934, anti-GAGA3: 
p = 0.663, anti-GAGA4: p = 0.712, and anti-GAGA6: 
p = 0.440).
No statistical differences between the gMS-Classi-
fier1 positive and negative group were observed for 
age (p = 0.631), disease duration (p = 0.147), gender 
(p = 0.154), baseline EDSS (p = 1.000), number of CIS 
patients at blood sampling (p = 0.865), follow-up time 
(p = 0.587), relapse at blood sampling (p = 0.771), and 
steroids at blood sampling (p = 1.000).
Here, we present the results of a large cohort of 
patients from different centers from two continents, 
showing no statistical differences between gMS-Clas-
sifier1 positive and negative patients, convincingly 
indicating that the gMS-Classifier1 does not predict 
disability progression in MS.
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Analysis of Canadian multiple sclerosis 
patients does not support a role for 
FKBP6 in disease
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We read with interest a recent article by Mescheriakova 
et al.1 entitled Linkage analysis and whole exome 
sequencing identify a novel candidate gene in a 
Dutch multiple sclerosis family. In this study, the 
authors described a missense variant in FKBP6 
(p.R183C, rs147213094) co-segregating with multi-
ple sclerosis (MS) in eight individuals from a large 
Dutch multi-incident family. Four healthy family 
members were also found to harbour this mutation, 
and it was not observed in one family member diag-
nosed with MS. Reduced penetrance and the pres-
ence of phenocopies does not detract from the 
authors’ claim as familial forms of complex diseases, 
including MS, frequently are genetically heterogene-
ous.2–5 In addition, albeit not statistically significant, 
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